# LifeMD, Inc.: overview

LFMD · Nasdaq · CIK 948320 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lfmd.md) · [Financials](/companies/lfmd/financials.md) · [Filings](/companies/lfmd/filings.md) · [Insiders](/companies/lfmd/insiders.md)

Latest reported revenue: [$47.3m](/filings/0001493152-26-036200.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-036200).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [53.3](/filings/0001493152-25-023906.md) | [5.5 d](/filings/0001493152-26-009549.md) | [50.9](/filings/0001493152-26-021536.md) | [49.0](/filings/0001493152-26-036200.md) | [60.2](/filings/0001493152-25-023906.md) | [7.1 d](/filings/0001493152-26-009549.md) | [50.2](/filings/0001493152-26-021536.md) | [47.3](/filings/0001493152-26-036200.md) |
| Gross margin | % | [90.6%](/filings/0001493152-25-023906.md) | [(24.0%) d](/filings/0001493152-26-009549.md) | [84.0%](/filings/0001493152-26-021536.md) | [86.0%](/filings/0001493152-26-036200.md) | [87.7%](/filings/0001493152-25-023906.md) | [40.2% d](/filings/0001493152-26-009549.md) | [88.2%](/filings/0001493152-26-021536.md) | [88.8%](/filings/0001493152-26-036200.md) |
| Operating margin | % | [(7.5%)](/filings/0001493152-25-023906.md) | [(108.8%) d](/filings/0001493152-26-009549.md) | [(2.3%)](/filings/0001493152-26-021536.md) | [(4.8%)](/filings/0001493152-26-036200.md) | [(3.3%)](/filings/0001493152-25-023906.md) | [(87.9%) d](/filings/0001493152-26-009549.md) | [(17.8%)](/filings/0001493152-26-021536.md) | [(15.1%)](/filings/0001493152-26-036200.md) |
| Net margin | % | [(8.7%)](/filings/0001493152-25-023906.md) | [(90.0%) d](/filings/0001493152-26-009549.md) | [(0.4%)](/filings/0001493152-26-021536.md) | [(3.3%)](/filings/0001493152-26-036200.md) | [(6.3%)](/filings/0001493152-25-023906.md) | [282.0% d](/filings/0001493152-26-009549.md) | [(17.7%)](/filings/0001493152-26-021536.md) | [(15.0%)](/filings/0001493152-26-036200.md) |
| Diluted EPS | $ per share | [(0.13)](/filings/0001493152-25-023906.md) | not reported | [(0.02)](/filings/0001493152-26-021536.md) | [(0.05)](/filings/0001493152-26-036200.md) | not reported | not reported | [(0.20)](/filings/0001493152-26-021536.md) | [(0.16)](/filings/0001493152-26-036200.md) |
| Free cash flow | $m | [6.3 d](/filings/0001493152-25-023906.md) | [0.9 d](/filings/0001493152-26-009549.md) | [3.0](/filings/0001493152-26-021536.md) | [7.9 d](/filings/0001493152-26-036200.md) | [(1.0) d](/filings/0001493152-25-023906.md) | [(3.4) d](/filings/0001493152-26-009549.md) | [0.3](/filings/0001493152-26-021536.md) | [(7.0) d](/filings/0001493152-26-036200.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [92.9](/filings/0001493152-23-008560.md) | [119](/filings/0001493152-24-009581.md) | [153](/filings/0001493152-25-009790.md) | [155](/filings/0001493152-26-009549.md) | [194](/filings/0001493152-26-009549.md) |
| Gross margin | % | [80.6%](/filings/0001493152-23-008560.md) | [84.3%](/filings/0001493152-24-009581.md) | [87.6%](/filings/0001493152-25-009790.md) | [86.2%](/filings/0001493152-26-009549.md) | [85.7%](/filings/0001493152-26-009549.md) |
| Operating margin | % | [(58.5%)](/filings/0001493152-23-008560.md) | [(36.5%)](/filings/0001493152-24-009581.md) | [(9.5%)](/filings/0001493152-25-009790.md) | [(13.2%)](/filings/0001493152-26-009549.md) | [(4.0%)](/filings/0001493152-26-009549.md) |
| Net margin | % | [(65.6%)](/filings/0001493152-23-008560.md) | [(38.3%)](/filings/0001493152-24-009581.md) | [(13.5%)](/filings/0001493152-25-009790.md) | [(13.8%)](/filings/0001493152-26-009549.md) | [7.4%](/filings/0001493152-26-009549.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | [(0.60)](/filings/0001493152-26-009549.md) | [0.25](/filings/0001493152-26-009549.md) |
| Free cash flow | $m | [(33.3)](/filings/0001493152-23-008560.md) | [(23.3)](/filings/0001493152-24-009581.md) | [8.6](/filings/0001493152-25-009790.md) | [16.0](/filings/0001493152-26-009549.md) | [6.4](/filings/0001493152-26-009549.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lfmd/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $12.5m | 3,034,535 |  | Added +225,510 |
| [FEDERATED HERMES, INC.](/funds/1056288.md) | 2026-06-30 | $11.3m | 2,747,655 |  | Added +1,728,578 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $7.2m | 1,734,756 |  | Added +71,060 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $5.4m | 1,318,784 |  | Added +243,376 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $4.5m | 1,079,525 |  | Reduced −38,800 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $4.4m | 1,067,698 |  | Added +48,257 |
| [Prescott Group Capital Management, L.L.C.](/funds/1166152.md) | 2026-06-30 | $3.7m | 897,224 |  | Added +1,800 |
| [BRC Group Holdings, Inc.](/funds/1464790.md) | 2026-06-30 | $2.6m | 637,319 |  | Reduced −234,261 |
| [ROYCE & ASSOCIATES LP](/funds/906304.md) | 2026-06-30 | $2.6m | 636,124 |  | Reduced −565,527 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $2.6m | 619,506 |  | Added +421,184 |

## Recent filings

[All 578 filings](/companies/lfmd/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-15 | 14:18 ET | [8-K](/filings/0001493152-26-042691.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-042691 |
| 2026-08-05 | 20:51 ET | [10-Q](/filings/0001493152-26-036200.md) | Quarterly report, period 2026-06-30 | 0001493152-26-036200 |
| 2026-08-05 | 20:10 ET | [8-K](/filings/0001493152-26-036170.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-036170 |
| 2026-06-22 | 12:25 ET | [8-K](/filings/0001493152-26-029503.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-029503 |
| 2026-05-06 | 21:24 ET | [10-Q](/filings/0001493152-26-021536.md) | Quarterly report, period 2026-03-31 | 0001493152-26-021536 |
| 2026-05-06 | 21:04 ET | [8-K](/filings/0001493152-26-021520.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-021520 |
| 2026-04-30 | 20:05 ET | [DEF 14A](/filings/0001493152-26-020419.md) | Proxy statement, period 2026-04-30 | 0001493152-26-020419 |
| 2026-03-18 | 20:16 ET | [8-K](/filings/0001493152-26-011228.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-011228 |
| 2026-03-10 | 20:56 ET | [10-K](/filings/0001493152-26-009549.md) | Annual report, period 2025-12-31 | 0001493152-26-009549 |
| 2026-03-09 | 20:37 ET | [8-K](/filings/0001493152-26-009380.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-009380 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-009549.md), filed Mar 10, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/03973d04-4d70-40f0-8089-42b0a9ec858d)

## About the filer

- CIK: 948320
- Tickers: LFMD, LFMDP
- Exchange: Nasdaq
- SIC code: 8011 Services-Offices & Clinics of  Doctors of  Medicine
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.